CAJ | 학술논문

Objective To investigate the effects of individualised treatment with peginterferon alpha-2a (40 kD) plus ribavirin in Chinese patients with CHC. Methods Total of 297 consecutive Chinese patients were enrolled, including 250 na?ve cases and 47 cases who were previously treated. Treatment duration was determined according to viral genotypes, prior treatment history and viral responses at week 4, 12 and 24. Results Totally, 235 patients (79.1%) completed treatment and 186 (87.3%) achieved SVR. And 219 out of 289 (75.8%) patients achieved HCV RNA negative at week 4 (RVR) and 259 of 276 (93.8%) at week 12. Among the 164 patients with RVR who completed follow-up, 158 (96.3%) achieved SVR. Patients with RVR had lower baseline viral loads than patients without RVR (P=0.034). The positive predictive value (PPV) of RVR for SVR was 90.7%(OR 2.10 vs. non-RVR, 95%CI:0.50-8.7). Similar outcomes were observed among patients with HCV undetectable at week 12. Conclusions Viral suppression by week 4 is associated with a high rate of treatment success in treatment na?ve and experienced patients receiving individualized CHC therapy.